These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 31724441)

  • 21. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
    Ratia K; Pegan S; Takayama J; Sleeman K; Coughlin M; Baliji S; Chaudhuri R; Fu W; Prabhakar BS; Johnson ME; Baker SC; Ghosh AK; Mesecar AD
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16119-24. PubMed ID: 18852458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.
    Paul A; Sarkar A; Saha S; Maji A; Janah P; Kumar Maity T
    Bioorg Med Chem; 2021 Sep; 46():116301. PubMed ID: 34332853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
    Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.
    Ramajayam R; Tan KP; Liu HG; Liang PH
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3569-72. PubMed ID: 20494577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs.
    Rajnarayanan RV; Dakshanamurthy S; Pattabiraman N
    Biochem Biophys Res Commun; 2004 Aug; 321(2):370-8. PubMed ID: 15358186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
    Tatar G; Salmanli M; Dogru Y; Tuzuner T
    J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.
    Konno H; Wakabayashi M; Takanuma D; Saito Y; Akaji K
    Bioorg Med Chem; 2016 Mar; 24(6):1241-54. PubMed ID: 26879854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.
    Ghosh AK; Takayama J; Aubin Y; Ratia K; Chaudhuri R; Baez Y; Sleeman K; Coughlin M; Nichols DB; Mulhearn DC; Prabhakar BS; Baker SC; Johnson ME; Mesecar AD
    J Med Chem; 2009 Aug; 52(16):5228-40. PubMed ID: 19645480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus.
    Goetz DH; Choe Y; Hansell E; Chen YT; McDowell M; Jonsson CB; Roush WR; McKerrow J; Craik CS
    Biochemistry; 2007 Jul; 46(30):8744-52. PubMed ID: 17605471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.
    Ramajayam R; Tan KP; Liu HG; Liang PH
    Bioorg Med Chem; 2010 Nov; 18(22):7849-54. PubMed ID: 20947359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors.
    Ghosh AK; Gong G; Grum-Tokars V; Mulhearn DC; Baker SC; Coughlin M; Prabhakar BS; Sleeman K; Johnson ME; Mesecar AD
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5684-8. PubMed ID: 18796354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.
    Griffin JWD
    J Struct Biol; 2020 Sep; 211(3):107575. PubMed ID: 32653646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.
    Lai L; Han X; Chen H; Wei P; Huang C; Liu S; Fan K; Zhou L; Liu Z; Pei J; Liu Y
    Curr Pharm Des; 2006; 12(35):4555-64. PubMed ID: 17168761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
    Yang S; Chen SJ; Hsu MF; Wu JD; Tseng CT; Liu YF; Chen HC; Kuo CW; Wu CS; Chang LW; Chen WC; Liao SY; Chang TY; Hung HH; Shr HL; Liu CY; Huang YA; Chang LY; Hsu JC; Peters CJ; Wang AH; Hsu MC
    J Med Chem; 2006 Aug; 49(16):4971-80. PubMed ID: 16884309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris.
    Nguyen TT; Woo HJ; Kang HK; Nguyen VD; Kim YM; Kim DW; Ahn SA; Xia Y; Kim D
    Biotechnol Lett; 2012 May; 34(5):831-8. PubMed ID: 22350287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV.
    Park JY; Ko JA; Kim DW; Kim YM; Kwon HJ; Jeong HJ; Kim CY; Park KH; Lee WS; Ryu YB
    J Enzyme Inhib Med Chem; 2016; 31(1):23-30. PubMed ID: 25683083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features.
    Chen L; Li J; Luo C; Liu H; Xu W; Chen G; Liew OW; Zhu W; Puah CM; Shen X; Jiang H
    Bioorg Med Chem; 2006 Dec; 14(24):8295-306. PubMed ID: 17046271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
    Ohnishi K; Hattori Y; Kobayashi K; Akaji K
    Bioorg Med Chem; 2019 Jan; 27(2):425-435. PubMed ID: 30558861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.
    Thanigaimalai P; Konno S; Yamamoto T; Koiwai Y; Taguchi A; Takayama K; Yakushiji F; Akaji K; Chen SE; Naser-Tavakolian A; Schön A; Freire E; Hayashi Y
    Eur J Med Chem; 2013 Oct; 68():372-84. PubMed ID: 23994330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.